Malaria vaccine development and how external forces shape it: An overview

International Journal of Environmental Research and Public Health

Volumn 11, Issue 7, 2014, Pages 6791-6807

  Lorenz, Veronique ^a   Karanis, Gabriele ^b,c   Karanis, Panagiotis ^a,b,c  

^a UNIVERSITY OF COLOGNE   (Germany)

^b OBIHIRO UNIVERSITY OF AGRICULTURE AND VETERINARY MEDICINE   (Japan)

^c QINGHAI UNIVERSITY   (China)

Author keywords

Malaria; Malaria life cycle; Malaria vaccine development

Indexed keywords

CHLORPHENOTANE; DNA VACCINE; MALARIA VACCINE;

LIFE CYCLE; MALARIA; VACCINATION; VACCINE;

BED NET; CLIMATE CHANGE; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); DNA IMMUNIZATION; DRUG EFFICACY; HEALTH CARE FINANCING; HOST PARASITE INTERACTION; HUMAN; IMMUNE EVASION; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; INFECTION RISK; LIFE CYCLE; MALARIA; MALARIA CONTROL; NONHUMAN; PARASITE DEVELOPMENT; PLASMODIUM FALCIPARUM; PLASMODIUM OVALE; PLASMODIUM VIVAX; REVIEW; SYSTEMATIC REVIEW; VACCINATION; MEDICAL RESEARCH;

BIOMEDICAL RESEARCH; HUMANS; MALARIA; MALARIA VACCINES; VACCINATION;

EID: 84904012006     PISSN: 16617827     EISSN: 16604601     Source Type: Journal    
DOI: 10.3390/ijerph110706791     Document Type: Review

References (51)

1. Theurer, M. Hoffnung im Kampf Gegen Malaria. Available online: http://www.faz.net/aktuell/wirtschaft/unternehmen/impfstoffe-hoffnung-im-kampf-gegen-malaria-1577621.html?offset=3 (accessed on 20 June 2014). (in German)
2. WHO Media Centre. Malaria. Available online: http://www.who.int/mediacentre/factsheets/fs094/en/index.html (accessed on 5 June 2014).
3. Gardner, M.J.; Hall, N.; Fung, E.; White, O.; Berriman, M.; Hyman, R.W.; Carlton, J.M.; Pain, A.; Nelson, K.E.; Bowman, S.; et al. Genome sequence of the human malaria parasite Plasmodium falciparum. Nature 2002, 419, 498-511.
4. Good, M.F. Towards a blood-stage vaccine for malaria: Are we following the leads? Nat. Rev. Immunol. 2001, 1, 117-125.
5. Löscher, T. Malaria-Entwicklungsland Deutschland? Dtsch Ärztebl. 1998, 95, 2694-2700. (in German).
6. Frimmel, S.; Hemmer, C.J.; Löbermann, M.; Reisinger, E.C. Wegbereiter für globale Ausbreitung tropischer Infektionskrankheiten? Klimawandel und globale Erwärmung. Pharmazie Unserer Zeit 2009, 38, 492-499. (in German)
7. Püschel, K.; Lockemann, U.; Dietrich, M. Malaria-Immer wieder Todesfälle infolge verspäteter Diagnose. Dtsch Ärztebl. 1998, 95, 2697-2700. (in German)
8. Krug, A. Mediziner Muss Wegen Fahrlässiger Tötung 6,300 Euro Zahlen; Süddeutsche Zeitung: München, Germany, 2005. (in German)
9. Zieger, B. Malaria in der Ärztlichen Praxis in Deutschland: Klinik, Fehldiagnosen, Therapie. Available online: http://www.auswaertiges-amt.de/diplo/de/Laenderinformationen/01-Laender/Gesundheitsdienst/Symposien/V/Zieger.pdf (accessed on 5 June 2014). (in German)
10. Lorenz, V.; Karanis, P. Malaria vaccines: Looking back and lessons learnt. Asian Pac. J. Trop. Biomed. 2011, 1, 74-78.
11. Packard, R.M. The Making of a Tropical Disease. A Short History of Malaria, 1st ed.; John Hopkins University Press: Baltimore, MD, USA, 2007.
12. Van den Berg, H. Global Status of DDT and Dann Alternatives for Use in Vector Control to Prevent Disease; Laboratory of Entomology, Wageningen University and Research Centre: Wageningen, The Netherlands, 2008.
13. Maher, B. The end of the beginning. Nature 2008, 451, 1042-1046.
14. Good, M.F. The hope but challenge for developing a vaccine that might control malaria. Eur. J. Immunol. 2009, 39, 939-943.
15. Schubert, C. Boosting our best shot. Nature 2009, 15, 984-988.
16. Olotu, A.; Fegan, G.; Wambua, J.; Nyangweso, G.; Awuondo, K.; Leach, A.; Lievenes, M.;Leboullex, D.; Njuguna, P.; Peshu, N.; et al. Four-year efficacy of RTS,S/AS01E and its interaction with malaria exposure. N. Engl. J. Med. 2013, 368, 1111-1120.
17. Doolan, D.L.; Hoffman, S.L. DNA-based vaccines against malaria: Status and promise of the multi-stage Malaria DNA vaccine operation. Int. J. Parasitol. 2001, 31, 753-762.
18. Holder, A.A. Malaria vaccines: Where next? PLoS Pathog. 2009, 5, doi:10.1371/journal.ppat.1000638.
19. Kraif, U. Das große Fremdwörterbuch, 4th ed.; Bibliographisches Institut: Mannheim, Germany, 2007. (in German)
20. Herold, G. Herold Innere Medizin 2010, 2010 ed.; Gerd Herold: Cologne, Germany, 2010. (in German)
21. Ewald, P.W. The Evolution of Infectious Disease; Oxford University Press: Oxford, UK, 1994.
22. Foote, S.J. Can nature's defence against malaria be mimicked by the development of host-directed therapies? Pharmacogenomics J. 2004, 4, 141-142.
23. Woodberry, T.; Pinzon-Charry, A.; Piera, K.A.; Panpisutchai, Y.; Engwerda, C.R.; Doolan, D.L.; Salwati, E.; Kenangalem, E.; Tjitra, E.; Price, R.N.; et al. Human T cell recognition of the blood stage antigen Plasmodium hypoxanthine guanine xanthine phosphoribosyl transferase (HGXPRT) in acute malaria. Malar. J. 2009, 8, doi:10.1186/1475-2875-8-122.
24. Luke, T.C.; Hoffman, S.L. Rationale and plans for developing a non-replicating, metabolically active radiation-attenuated Plasmodium falciparum sporozoite vaccine. J. Exp. Biol. 2003, 206, 3803-3808.
25. Bedford, H.; Elliman, D. Concerns about immunisation. BMJ 2000, 320, 240-243.
26. Lavazec, C.; Bourgouin, C. Mosquito-based transmission-blocking vaccines for interrupting Plasmodium development. Microbes Infect. 2008, 10, 845-849.
27. Kubler-Kielb, J.; Majadly, F.; Narum, D.L.; Gue, C.; Miller, L.H.; Shiloach, J.; Schneerson, R. Long lasting and transmission-blocking activity of antibodies to P. falciparum elicited in mice by protein conjugates of Pfs25. Proc. Nat. Acad. Sci. USA 2006, 104, 293-298.
28. Cohen, S. Progress in malaria vaccine development. Brit. Med. Bull. 1982, 38, 161-166.
29. Nussenzweig, R.S.; Vanderberg, J.; Most, H.; Orton, C. Protective immunity produced by the injection of X-irradiated sporozoites of Plasmodium berghei. Nature 1967, 216, 160-162.
30. Ménard, R.; Heussler, V.; Yuda, M.; Nussenzweig, V. Plasmodium pre-erythrocytic stages: What's new? Trends Parasitol. 2008, 24, 564-569.
31. Nussenzweig, R.S.; Long, C.A. Malaria vaccines: Multiple targets. Science 1994, 265, 1381-1383.
32. Greenwood, B.; Targett, G. Do we still need a malaria vaccine? Parasite Immunol. 2009, 31, 582-586.
33. Intermittent Preventive Treatment of Malaria for Pregnant Women (IPTp); Centers for Disease Control and Prevention: Atlanta, GA, USA, 2010.
34. The State of Global Malaria Vaccine Development; PATH Malaria Vaccine Initiative: Washington, DC, USA, 2007.
35. Sinnis, P.; Coppi, A. A long and winding road: The Plasmodium sporozoite's journey in the mammalian host. Parasitol. Int. 2007, 56, 171-178.
36. Da'Dara, A.A.; Harn, D.A. DNA vaccines against tropical parasitic diseases. Expert Rev. Vaccines 2005, 4, 575-589.
37. Sherman, I.W. The Elusive Malaria Vaccine: Miracle or Mirage? 1st ed.; ASM Press: Washington, DC, USA, 2009.
38. Da Silva, H.B.; Caetano, S.S.; Monteiro, I.; Gómez-Conde, I.; Hanson, K.; Penha-Gonçalves, C.; Olivieri, D.N.; Mota, M.M.; Marinho, C.R.; D'Imperio Lima, M.R.; et al. Early skin immunological disturbance after Plasmodium-infected mosquito bites. Cell. Immunol. 2012, 277, 22-32.
39. Combadière, B.; Mahé, B. Particle-based vaccines for transcutaneous vaccination. Comp. Immunol. Microbiol. Infect. Dis. 2008, 31, 293-315.
40. Sinnis, P.; Zavala, F. The skin stage of malaria infection: Biology and relevance to the malaria vaccine effort. Future Microbiol. 2008, 3, 275-278.
41. Cranenburgh, R. Needle-free Methods of Vaccination. Available online: http://biopharminternational.findpharma.com/biopharm/Downstream+Processing/Needle-Free-Methods-of-Vaccination/ArticleStandard/Article/detail/485192 (accessed on 9 December 2010).
42. Amino, R.; Giovannini, D.; Thiberge, S.; Gueirard, P.; Boisson, B.; Dubremetz, J.F.; Prévost, M.C.; Ishino, T.; Yuda, M.; Ménard, R. Host cell traversal is important for progression of the malaria parasite through the dermis to the liver. Cell Host Microbe. 2008, 3, 88-96.
43. Kutzler, M.A.; Weiner, D.B. DNA vaccines: Ready for prime time? Nat. Rev. Genet. 2008, 9, 776-788.
44. Khan, K.H. DNA vaccines: Roles against diseases. Germs 2013, 3, 26-35.
45. Kalinna, B.H. DNA vaccines for parasitc infections. Immunol. Cell Biol. 1997, 75, 370-375
46. Bergman, P.J.; Camps-Palau, M.A.; McKnight, J.A.; Leibman, N.F.; Craft, D.M.; Leung, C.; Liao, J.; Riviere, I.; Sadelain, M.; Hohenhaus, A.E.; et al. Development of a xenogenic DNA vaccine program for canine malignant melanoma at the Animal Medical Center. Vaccine 2006, 24, 4582-4585.
47. Holtel, A.; Ghalouci, R. EU-funded Malaria Research under Framework Programmes 6 and 7. Available online: http://ec.europa.eu/research/health/infectious-diseases/poverty-diseases/doc/eu-funded-malaria-research-leaflet_en.pdf (accessed on 5 June 2014).
48. Callaway, E. Malaria research should go back to basics. Nature 2007, 449, doi:10.1038/449266b.
49. Offit, P. Why are pharmaceutical companies gradually abandoning vaccines? Health Affair. 2005, 24, 622-630.
50. André, F.E. Vaccinology: Past achievements, present roadblocks and future promises. Vaccine 2003, 21, 593-595.
51. Jarasch, E. Impfstoffentwicklung; Das Biotechnologie und Life Sciences Portal: Baden-Württemberg, Germany, 2010.